What is HC Wainwright’s Estimate for APRE FY2024 Earnings?

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Equities research analysts at HC Wainwright boosted their FY2024 earnings per share estimates for Aprea Therapeutics in a research report issued to clients and investors on Monday, November 18th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($2.39) per share for the year, up from their prior forecast of ($2.41). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($2.55) per share. HC Wainwright also issued estimates for Aprea Therapeutics’ Q4 2024 earnings at ($0.54) EPS, FY2025 earnings at ($0.95) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.61) EPS.

Separately, Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Aprea Therapeutics Stock Performance

NASDAQ:APRE opened at $2.92 on Wednesday. The stock’s fifty day moving average price is $3.31 and its two-hundred day moving average price is $3.84. The company has a market cap of $15.87 million, a price-to-earnings ratio of -1.04 and a beta of 0.97. Aprea Therapeutics has a 52-week low of $2.15 and a 52-week high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.11. The company had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.45 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%.

Insider Buying and Selling

In related news, Director Marc Duey acquired 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was acquired at an average price of $4.39 per share, for a total transaction of $131,700.00. Following the completion of the acquisition, the director now owns 240,113 shares of the company’s stock, valued at $1,054,096.07. This trade represents a 14.28 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bernd R. Seizinger bought 10,000 shares of Aprea Therapeutics stock in a transaction on Friday, October 11th. The shares were bought at an average price of $2.68 per share, for a total transaction of $26,800.00. Following the acquisition, the director now owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. The trade was a 28.79 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 42,290 shares of company stock valued at $165,096 over the last ninety days. Insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC acquired a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics makes up approximately 0.5% of Stonepine Capital Management LLC’s holdings, making the stock its 21st largest position. Stonepine Capital Management LLC owned about 2.53% of Aprea Therapeutics as of its most recent SEC filing. Institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.